Commercially reasonable efforts (CRE) provisions are a common feature in technology and life sciences agreements, particularly in development collaborations, licensing deals, and milestone-based contracts. ...more
3/27/2025
/ Commercially Reasonable Efforts ,
Contract Disputes ,
Contract Terms ,
Dispute Resolution ,
Intellectual Property Litigation ,
Life Sciences ,
Litigation Strategies ,
Pharmaceutical Industry ,
Research and Development ,
Risk Management ,
Technology Sector
In Wisconsin Alumni Research Foundation v. Apple, the Federal Circuit expanded the preclusive effect of non-infringement rulings. It ruled that prior judgments of non-infringement can prevent follow-on lawsuits involving...more
10/1/2024
/ America Invents Act ,
Apple ,
Claim Preclusion ,
Doctrine of Equivalents ,
Noninfringement ,
Obviousness-Type Double Patenting (ODP) ,
Patent Infringement ,
Patent Litigation ,
Patent Term Adjustment ,
Patent Terms ,
Patents ,
Safe Harbors ,
USPTO
In recent months, the issue of whether certain patents are appropriately listed in the Food and Drug Administration (FDA) Orange Book, associated with the Hatch-Waxman Act, has garnered the attention of the Federal Trade...more
6/18/2024
/ Abbreviated New Drug Application (ANDA) ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
Hatch-Waxman ,
Medical Devices ,
Orange Book ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs
Trade secret litigation is on the rise, and new case law related to enforceability has broad implications for how companies protect information that they consider to be trade secrets.
The Lex Machina 2020 Trade Secret...more
2/25/2021
/ Confidential Information ,
Corporate Counsel ,
Defend Trade Secrets Act (DTSA) ,
Employer Liability Issues ,
Exit Interviews ,
Former Employee ,
Intellectual Property Protection ,
Life Sciences ,
Patent Litigation ,
Technology ,
Trade Secrets
Written Description of Therapeutic Efficacy -
In two 2019 rulings, the Federal Circuit invoked the “written description requirement” of 35 U.S.C. § 112 to require evidentiary support for therapeutic efficacy. Now that the...more
2/24/2021
/ Appeals ,
Copyright ,
Defend Trade Secrets Act (DTSA) ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Misappropriation ,
Patent-Eligible Subject Matter ,
Pharmaceutical Patents ,
Section 101 ,
Social Media ,
Trade Secrets ,
USPTO ,
Written Descriptions